The Efficacy of Pharmacological Treatment in Pediatric Nonalcoholic Fatty Liver Disease
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: With growing number of obese children, the prevalence of nonalcoholic fatty liver disease (NAFLD) in pediatric population is increasing. Nonalcoholic steatohepatitis (NASH) is a severe form of NAFLD, and can cause morbid complications. It is important to identify patients in order to grade pathologic severities and treat those children who possibly have NASH. This study was performed to evaluate whether the pharmacological therapy is also effective as well as the body weight reduction in pediatric NAFLD. Methods: Among the 52 children presenting with obesity and hepatopathy, NAFLD was diagnosed through liver biopsy in 29 children, who were 7 to 14 years of age, from January 2006 to December 2011. The patients were advised to reduce their body weight through diverse methods. Medication with Ursodeoxycholic acid (UDCA) and vitamin E was performed in children whose liver functions did not improve or their weight reductions were not successful. The therapeutic effects were monitored and assessed via the biochemical profiles and the physical measurements. Results: The therapy of vitamin E and UDCA combined with body mass index (BMI) reduction showed significantly higher rate of improvement in clinical profiles, which could be seen in data of aspartate aminotransferase (AST), alanine aminotransferase (ALT), AST/ALT ratio, alkaline phosphatase, total bilirubin and γ-glutamyl transpeptidase. Children whose BMI were successfully reduced showed favorable clinical improvements without any medication, but those without BMI reduction did not show any improvement despite medications. Conclusion: This study showed that the first line of therapy should be the BMI reduction in NAFLD and drug therapy combined with BMI reduction could have additive therapeutic effect in children with NAFLD.
Abstract
Purpose: With growing number of obese children, the prevalence of nonalcoholic fatty liver disease (NAFLD) in pediatric population is increasing. Nonalcoholic steatohepatitis (NASH) is a severe form of NAFLD, and can cause morbid complications. It is important to identify patients in order to grade pathologic severities and treat those children who possibly have NASH. This study was performed to evaluate whether the pharmacological therapy is also effective as well as the body weight reduction in pediatric NAFLD. Methods: Among the 52 children presenting with obesity and hepatopathy, NAFLD was diagnosed through liver biopsy in 29 children, who were 7 to 14 years of age, from January 2006 to December 2011. The patients were advised to reduce their body weight through diverse methods. Medication with Ursodeoxycholic acid (UDCA) and vitamin E was performed in children whose liver functions did not improve or their weight reductions were not successful. The therapeutic effects were monitored and assessed via the biochemical profiles and the physical measurements. Results: The therapy of vitamin E and UDCA combined with body mass index (BMI) reduction showed significantly higher rate of improvement in clinical profiles, which could be seen in data of aspartate aminotransferase (AST), alanine aminotransferase (ALT), AST/ALT ratio, alkaline phosphatase, total bilirubin and γ-glutamyl transpeptidase. Children whose BMI were successfully reduced showed favorable clinical improvements without any medication, but those without BMI reduction did not show any improvement despite medications. Conclusion: This study showed that the first line of therapy should be the BMI reduction in NAFLD and drug therapy combined with BMI reduction could have additive therapeutic effect in children with NAFLD.
참고문헌 (25)
- Loomba R, "Advances in pediatric nonalcoholic fatty liver disease", Hepatology, 50, pp.1282~1293 (2009)
- Park HS, "Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents", Am J Clin Nutr, 82, pp.1046~1051 (2005)
- Tominaga K, "Prevalence of fatty liver in Japanese children and relationship to obesity", Dig Dis Sci, 40, pp.2002~2009 (1995)
- Widhalm K, "Nonalcoholic fatty liver disease: a challenge for pediatricians", Int J Obes (Lond), 34, pp.1451~1467 (2010)
- Mencin AA, "Nonalcoholic fatty liver disease in children", Curr Opin Clin Nutr Metab Care, 14, pp.151~157 (2011)
- Dufour JF, "Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis", Clin Gastroenterol Hepatol, 4, pp.1537~1543 (2006)
- Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
- 서정완, "소아 비알코올 지방간질환의 최신지견", Pediatric Gastroenterology, Hepatology & Nutrition, 14(3), pp.209~221 (2011), 대한소아소화기영양학회
- Manco M, "Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis", Int J Obes (Lond), 32, pp.381~387 (2008)
- Nobili V, "Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 7, pp.575~579 (2009)
- Alkhouri N, "A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis", Clin Gastroenterol Hepatol, 9, pp.150~155 (2011)
- Nobili V, "Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease", Pediatr Res, 67, pp.665~670 (2010)
- 지수정, "소아 비알코올성 지방간질환의 병리 소견과 임상적, 영상학적소견의 상관성", 대한소화기학회지, 57(3), pp.158~165 (2011), 대한소화기학회
- Nobili V, "NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice", Hepatology, 44, pp.458~465 (2006)
- Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association", Hepatology, 55, pp.2005~2023 (2012)
- Houmard JA, "Effect of the volume and intensity of exercise training on insulin sensitivity", J Appl Physiol, 96, pp.101~106 (2004)
- Paumgartner G, "Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 2004;8:67-81", Clin Liver Dis, 8, pp.67~81 (2004)
- Laurin J, "Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study", Hepatology, 23, pp.1464~1467 (1996)
- Lindor KD, "Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial", Hepatology, 39, pp.770~778 (2004)
- Leuschner UF, "High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial", Hepatology, 52, pp.472~479 (2010)
- Ratziu V, "A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis", J Hepatol, 54, pp.1011~1019 (2011)
- Strauss RS, "Comparison of serum concentrations of alpha-tocopherol and beta-carotene in a cross-sectional sample of obese and nonobese children (NHANES III). National Health and Nutrition Examination Survey", J Pediatr, 134, pp.160~165 (1999)
- Hasegawa T, "Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study", Aliment Pharmacol Ther, 15, pp.1667~1672 (2001)
- Harrison SA, "Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis", Am J Gastroenterol, 98, pp.2485~2490 (2003)
- Lavine JE, "Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial", JAMA, 305, pp.1659~1668 (2011)